Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.

[1]  S. Agrawal,et al.  Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia , 2009, International journal of hematology.

[2]  H. Goubran.  Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report , 2009, Journal of medical case reports.

[3]  He Huang,et al.  Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population , 2009, International journal of hematology.

[4]  W. Au,et al.  Chronic myeloid leukemia in Asia , 2009, International journal of hematology.

[5]  Yoo-Jin Kim,et al.  Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy , 2009, Leukemia & lymphoma.

[6]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Baccarani,et al.  Diagnosis and management of chronic myeloid leukemia , 2007, Cancer.

[8]  Z. Aziz,et al.  Treatment of chronic myeloid leukemia in the imatinib era , 2007, Cancer.

[9]  J. Cayuela,et al.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.

[10]  J. Lipton,et al.  Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia , 2006, Current oncology.

[11]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[12]  L. Kumar.  Chronic myelogenous leukaemia (CML): an update. , 2006, The National medical journal of India.

[13]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[14]  R. Larson,et al.  Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Martin C. Müller,et al.  Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center , 2005, Cancer.

[16]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[17]  K. Meehan,et al.  Chronic myelogenous leukemia. Curable with early diagnosis and treatment. , 1999, Postgraduate medicine.

[18]  Z. Estrov,et al.  Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.

[19]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.